Long Non-Coding RNA MALAT1 Gene Polymorphism is Associated with Disease-Free Survival in Bladder Cancer Patients


bladder cancer
gene polymorphism


The objective of the research was to study the possible association between MALAT1 gene rs3200401 polymorphism and the survival of patients with bladder cancer and clinicopathological characteristics in bladder cancer.

Materials and Methods. The venous blood of 141 patients with transitional cell carcinoma of the urinary bladder was used for study. Genotyping of MALAT1 gene rs3200401 polymorphism was performed by real-time polymerase chain reaction using the 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, USA) and Taq-Man Assays (TaqMan® SNP Assay C_3246069_10). Statistical analysis was performed using the SPSS software package (version 17.0). The Kaplan-Meier estimator and Cox regression were used to check the possible association between MALAT1 rs3200401-genotypes and the age of transitional cell carcinoma of the urinary bladder onset. P values ​​< 0.05 were considered as statistically significant.

Results. The obtained results revealed that hemoglobin concentration was lower in patients with transitional cell carcinoma of the urinary bladder and rs3200401TT-genotype than in patients with rs3200401CC-genotype (p=0.024). Herewith, fasting glucose, creatinine concentration, and tumor width were significantly higher in patients with transitional cell carcinoma of the urinary bladder and rs3200401TT-genotype as compared to rs3200401CC-genotype carriers (p = 0.036, p = 0.039, p = 0.028, respectively). The results of survival analysis demonstrated that transitional cell carcinoma of the urinary bladder occurred much later in persons with rs3200401TT-genotype as compared to rs3200401C-allele carriers (log rank p = 0.016), and the risk of transitional cell carcinoma of the urinary bladder onset was lower in individuals with rs3200401TT than in major rs3200401C C-allele carriers (hazard ratio = 0.413; p = 0.047).

Conclusions. Rs3200401 polymorphism of MALAT1 gene is associated with disease-free survival in Ukrainian patients with transitional cell carcinoma of the urinary bladder. Transitional cell carcinoma of the urinary bladder occurs later in persons with rs3200401TT-genotype than in individuals with rs3200401CC- and rs3200401CT-genotypes.



Ulitsky I, Shkumatava A, Jan CH et al. Conserved function of lincRNAs in vertebrate embryonic development despite rapid sequence evolution. Cell. 2011; 147 (7): 1537-1550. DOI: https://doi.org/10.1016/j.cell.2011.11.055 [PMid:22196729 PMCid:PMC3376356]

Marx SJ. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat Rev Cancer. 2005; 5 (5): 367-375. DOI: https://doi.org/10.1038/nrc1610 [PMid:15864278]

Ji P, Diederichs S, Wang W et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene. 2003; 22 (39): 8031-8041. DOI: https://doi.org/10.1038/sj.onc.1206928 [PMid:12970751]

Sun Y, Ma L. New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis. Cancers. 2019; 11 (2): E216. DOI: https://doi.org/10.3390/cancers11020216 [PMid:30781877 PMCid:PMC6406606]

Zhang X, Hamblin H, Yin KJ. The long noncoding RNA Malat1: Its physiological and pathophysiological functions. RNA Biol. 2017; 14 (12): 1705-1714. DOI: https://doi.org/10.1080/15476286.2017.1358347 [PMid:28837398 PMCid:PMC5731810]

Ying L, Chen Q, Wang Y et al. Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst. 2012; 8 (9): 2289-2294. DOI: https://doi.org/10.1039/c2mb25070e [PMid:22722759]

Xie H, Liao X, Chen Z et al. LncRNA MALAT1 Inhibits Apoptosis and Promotes Invasion by Antagonizing miR-125b in Bladder Cancer Cells. J Cancer. 2017; 8 (18): 3803-3811. DOI: https://doi.org/10.7150/jca.21228 [PMid:29151968 PMCid:PMC5688934]

Li C, Cui Y, Liu LF et al. High Expression of Long Noncoding RNA MALAT1 Indicates a Poor Prognosis and Promotes Clinical Progression and Metastasis in Bladder Cancer. Clin Genitourin Cancer. 2017; 15 (5): 570-576. DOI: https://doi.org/10.1016/j.clgc.2017.05.001 [PMid:28648755]

Zhan Y, Du L, Wang L et al. Expression signatures of exosomal long non-coding RNAs in urine serve as novel non-invasive biomarkers for diagnosis and recurrence prediction of bladder cancer. Mol Cancer. 2018; 17 (1): 142. DOI: https://doi.org/10.1186/s12943-018-0893-y [PMid:30268126 PMCid:PMC6162963]

Peng R, Luo C, Guo Q et al. Association analyses of genetic variants in long non-coding RNA MALAT1 with breast cancer susceptibility and mRNA expression of MALAT1 in Chinese Han population. Gene. 2018; 642: 241-248. [] DOI: https://doi.org/10.1016/j.gene.2017.11.013 [PMid:29146194]

Wang JZ, Xiang JJ, Wu LG et al. A genetic variant in long non-coding RNA MALAT1 associated with survival outcome among patients with advanced lung adenocarcinoma: a survival cohort analysis. BMC Cancer. 2017; 17 (1): 167. DOI: https://doi.org/10.1186/s12885-017-3151-6 [PMid:28253859 PMCid:PMC5335789]

Alfred Witjes J, Lebret T, Compé rat EM et al. Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2017; 71 (3): 462-475. DOI: https://doi.org/10.1016/j.eururo.2016.06.020 [PMid:27375033]

Babjuk M, Bö hle A, Burger M et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol. 2017; 71 (3): 447-461. DOI: https://doi.org/10.1016/j.eururo.2016.05.041 [PMid:27324428]

Paner GP, Stadler WM, Hansel DE et al. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018; 73 (4): 560-569. DOI: https://doi.org/10.1016/j.eururo.2017.12.018 [PMid:29325693]


Wang G, Li Y, Peng Y et al. Association of polymorphisms in MALAT1 with risk of coronary atherosclerotic heart disease in a Chinese population. Lipids Health Dis. 2018; 17 (1): 75. DOI: https://doi.org/10.1186/s12944-018-0728-2 [PMid:29631611 PMCid:PMC5891990]

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


Download data is not yet available.